Your session is about to expire. Click Ok to extend or Cancel to log out.

Your session has expired. Please log in again.

Article

Global Access Program

Working hand in hand to provide innovative diagnostic solutions to those who need it most

More than 35 million people are currently living with HIV

Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organizations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.

As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.

"We applaud all the global partners who came together to ensure that over 31 million people living with HIV/AIDS in low- and middle-income countries will be able to access viral load testing at this reduced price."

President Bill Clinton, Chairman of the Clinton Health Access Initiative

"We welcome this significant price breakthrough – the urgent call of people living with HIV is being answered. Now, with viral load testing, we can help ensure HIV treatment improves quality of life."

Michel Sidibé, UNAIDS Executive Director

playicon

Take aim at HIV

playicon

videoCtrl

/

fullScreen

Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.

Take aim at HIV

Uncover the impact of accessible HIV diagnostics.

playicon

An innovative approach

playicon

videoCtrl

/

fullScreen

Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.

HIV at a glance

By 2020...

*Adults and children estimated to be living with HIV in 2014 and 2020, assuming infection rates remain the same.

Targeting 90-90-90 with optimized diagnostic testing

The Global Access Program contributes to the goals of 90-90-90 by providing diagnostic products for early infant diagnosis and viral load testing.

Early Infant Diagnosis

Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV Qualitative assay provides reliable, accurate information on whether or not an infant is infected.

Dry blood spot

The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting small blood on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.

Viral Load Testing

Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.

Modal Title

Some randomr randomr randomr randomr randomr randomr

Our policy on cookies and other tracking technologies

This website uses cookies to deliver content that is tailored to your interests and preferences and to otherwise administer and improve the site. Some functionality may not be available should you choose to not accept.